Concept:
Oxcarbazepine is a widely used antiepileptic drug, primarily effective for focal (partial) onset seizures. It is a structural derivative of carbamazepine.
Board examinations frequently test knowledge regarding the unique, dose-limiting, and clinically significant adverse effect profiles of specific antiepileptic drugs.
Explanation:
• A prominent, specific, and well-known adverse effect of Oxcarbazepine is clinically significant hyponatremia.
• The mechanism by which oxcarbazepine induces hyponatremia is not entirely understood but is largely attributed to a Syndrome of Inappropriate Antidiuretic Hormone (SIADH)-like effect, where the drug increases the sensitivity of the renal collecting duct tubules to circulating ADH (vasopressin), leading to inappropriate free water retention and dilutional hyponatremia.
• Interestingly, although oxcarbazepine was developed to have a cleaner side effect profile and fewer drug-drug interactions than its parent drug carbamazepine, the incidence of hyponatremia is actually *higher* with oxcarbazepine (occurring in up to 20-30% of patients).
• Routine monitoring of serum sodium levels is recommended in patients on this medication, particularly the elderly or those on concurrent diuretics.
• Option (B), Hepatotoxicity, is a classic, severe (black box warning) adverse effect of Valproic Acid.
• Option (C), Gingival hyperplasia, is a hallmark, specific adverse effect of chronic Phenytoin use.
• Option (D), Weight gain, is a very common and frustrating side effect associated with Valproic Acid, Pregabalin, and Gabapentin, but less so with oxcarbazepine.
Final answer:
Hyponatremia is the most characteristic and clinically significant metabolic side effect associated with Oxcarbazepine therapy.